Owkin
Founded Year
2016Stage
Corporate Minority | AliveTotal Raised
$334.1MLast Raised
$80M | 3 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+110 points in the past 30 days
About Owkin
Owkin is an AI biotechnology company that employs artificial intelligence to improve drug discovery and development in the biopharmaceutical sector. The company specializes in AI-based identification of new treatments, clinical trial optimization, and diagnostic tool creation, while ensuring patient privacy through federated learning techniques. Owkin serves the biopharma and academic research communities. It was founded in 2016 and is based in New York, New York.
Loading...
ESPs containing Owkin
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The life sciences AI model developers market employs specialized AI models to process and interpret complex biological data across multiple scales. These include foundational models and large language models for applications such as molecular analysis, protein design, and drug discovery. This market primarily serves pharmaceutical and biotechnology companies seeking to accelerate scientific discov…
Owkin named as Leader among 13 other companies, including Google, NVIDIA, and InstaDeep.
Owkin's Products & Differentiators
Owkin K
Owkin K is a plug-and-play AI copilot designed to revolutionize biomedical research and drug development. To be launched in May 2025.
Loading...
Research containing Owkin
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Owkin in 7 CB Insights research briefs, most recently on Mar 17, 2025.
Aug 21, 2024
The clinical trials tech market map
Oct 13, 2023
The open-source AI development market map
Aug 10, 2023
The oncology tech market map
Expert Collections containing Owkin
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Owkin is included in 8 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,276 items
AI 100 (All Winners 2018-2025)
400 items
Digital Health 50
300 items
The most promising digital health startups transforming the healthcare industry
Conference Exhibitors
5,302 items
Digital Health
11,408 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Precision Medicine Tech Market Map
160 items
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
Owkin Patents
Owkin has filed 13 patents.
The 3 most popular patent topics include:
- machine learning
- artificial neural networks
- classification algorithms
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
12/30/2022 | 3/11/2025 | Machine learning, Artificial neural networks, Classification algorithms, Artificial intelligence, Machine learning algorithms | Grant |
Application Date | 12/30/2022 |
|---|---|
Grant Date | 3/11/2025 |
Title | |
Related Topics | Machine learning, Artificial neural networks, Classification algorithms, Artificial intelligence, Machine learning algorithms |
Status | Grant |
Latest Owkin News
Jun 26, 2025
融资2.7亿，服务28万癌症患者，Outcomes4Me用AI技术改进癌症护理模式 截止目前，Outcomes4Me总融资额达到3800万美元（约2.7亿元），这些资金将用来进一步开发其核心产品——AI驱动的癌症护理平台，为患者提供更加个性化和智能化的解决方案，以改善癌症护理体验。 （Outcomes4Me融资历程，动脉网制图） 癌症护理需破解信息化能力不足的缺陷 据《2022年全球癌症统计报告》，2022年全球新发癌症病例1997.6万例，死亡病例达974.4万例。随着全球癌症患病人数的激增，人们对于癌症护理的需求也相应提高。 但目前癌症护理仍面临一些临床痛点： 其次，患者了解临床试验的渠道有限，这也成为临床试验匹配率低的原因之一。而临床试验对于一些“无药可医”和家庭经济困难的患者来说，或许是一次重获新生的希望。 再次，病例记录、随访信息等数据碎片化地分布在多个平台，患者极有可能出现“头痛医头，脚痛医脚”的现象，严重影响治疗连续性。 在此背景下，信息的“流动”成为一大关键。换言之，更加智能的医疗数据搜集、整理和分析对于癌症护理患者来说已然成为亟待解决的问题。 Outcomes4Me的AI癌症护理平台正是针对此需求进行的研发。该平台有三大核心功能：提供个性化治疗建议、临床试验匹配和症状追踪。 临床试验匹配，提高患者治疗参与率：该平台利用AI算法整合来自美国和加拿大700多家医疗机构的临床试验数据，筛选全球范围内的临床试验，帮助患者找到适合其癌症类型和分期的研究项目，可以缩短患者与试验的对接时间，解决了当前癌症患者获取临床试验的渠道不足的痛点，从而提高他们的治疗参与率。 症状追踪，优化护理管理：患者可通过App记录治疗过程中的症状（如疼痛、疲劳等），并与医疗团队共享数据，优化护理管理。值得一提的是，该App符合美国医疗隐私法规，会确保患者数据安全。 据Outcomes4Me官网，患者可免费下载并使用这款App，目前，Outcomes4Me已累计有28万用户。未来，这款App若能进一步覆盖更多适应症，并拿下FDA认证，其影响力将显著提升。 从全球范围来看，Outcomes4Me的同类产品还有PathAI公司的AI Sight图像管理系统 、Owkin的MSIntuit CRC数字病理解决方案等，它们都是基于AI驱动的癌症护理平台，旨在帮助癌症患者更好地理解病情、优化治疗方案并匹配临床试验。 AI赋能护理，助力精准、智慧医疗建设 从政策端来看，2024年11月，国家卫生健康委、国家中医药局、国家疾控局联合发布了《卫生健康行业人工智能应用场景参考指引》，明确了AI技术在13项大类、84个细分的应用场景，这意味着AI将加速应用于医疗行业中，为患者提供更智能、更高效、更精准的医疗服务。 我国在 AI驱动的癌症护理平台领域发展迅速，已涌现出了“CSCO AI 智能辅助决策系统”（海心智惠）、“蚂蚁集团AI健康管家”、“阿里健康 CACA-AI智惠基层科普赋能工程”等一系列数智化平台。 在需求和政策合力作用下，仅在2025年上半年，这些数智化平台就动作频频。4月，阿里健康携手中国抗癌协会启动“健康智医 CACA-AI智惠基层科普赋能工程”，以AI技术普惠基层；5月，CSCO、海心智惠和蚂蚁健康共同发布中国乳腺专科智能体CSCO AI Pro，动态分析患者个体特征，为医生提供精准高效的实时临床支持。 不少医院也紧跟时代步伐，积极探索“ AI +护理”技术的多元应用。中山大学孙逸仙纪念医院肿瘤科护理团队于6月推出了"症状评估-AI匹配-VR干预"一体化终端，为患者提供“ 一人一策’精准护理方案”。 因癌症治疗的特殊性，出院后面临复发、疾病治疗与监测信息来源中断、疾病保健与药物管 理知识匮乏等一系列问题，癌症病人对信息的需求更加迫切，信息的延续对他们来说十分重要。未来，AI技术将进一步融入医疗健康行业，相信本土会诞生更多“AI+癌症护理”的产品，并覆盖更多癌种，来满足不断增长的患者的需求。 该文观点仅代表作者本人，36氪平台仅提供信息存储空间服务。
Owkin Frequently Asked Questions (FAQ)
When was Owkin founded?
Owkin was founded in 2016.
Where is Owkin's headquarters?
Owkin's headquarters is located at 831 Broadway, New York.
What is Owkin's latest funding round?
Owkin's latest funding round is Corporate Minority.
How much did Owkin raise?
Owkin raised a total of $334.1M.
Who are the investors of Owkin?
Investors of Owkin include Bristol-Myers Squibb, Sanofi Ventures, EIT Health Gold Track, Plug and Play, Plug and Play Ventures and 15 more.
Who are Owkin's competitors?
Competitors of Owkin include Imagene AI, InSilicoTrials, Savana, Rhino Federated Computing, Aqemia and 7 more.
What products does Owkin offer?
Owkin's products include Owkin K.
Loading...
Compare Owkin to Competitors
PathAI provides artificial intelligence (AI)-powered research tools and services for pathology. It delivers the diagnosis and treatment of cancer by leveraging modern approaches in machine learning. The company offers biopharmacy lab services, clinical development services, drug and diagnostic development, and more. It was founded in 2016 and is based in Boston, Massachusetts.
Insilico Medicine focuses on artificial intelligence in drug discovery and development. The company provides artificial intelligence platforms for multi-omics target discovery, deep biology analysis, automated drug design, and predicting outcomes in clinical trials. The technologies are intended to assist in the process of discovering and developing new medications for various diseases. It was founded in 2014 and is based in New Territories, Hong Kong.
Paige specializes in diagnostic artificial intelligence (AI) for the healthcare sector, focusing on cancer care. The company provides AI-assisted applications for cancer detection, subtyping, and molecular biomarker discovery, along with technology and services intended to support research and development in computational pathology. Paige serves the healthcare and life sciences sectors with its AI technology and services. It was founded in 2017 and is based in New York, New York.
Evidation is involved in measuring health in everyday life within the digital health sector. The company provides a platform for individuals to track health activities, participate in research, and manage their data privacy. Evidation serves the life sciences, government, and non-profit organizations. It was founded in 2012 and is based in San Mateo, California.
Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.
Aitia operates as a biotechnology company. It utilizes causal artificial intelligence (AI), multi-omic patient data, and Gemini Digital Twins to study the biological mechanisms of diseases in the oncology and neurodegenerative disease sectors. The company aims to create computational representations of diseases to assist in the development of therapies. It was founded in 2000 and is based in Somerville, Massachusetts.
Loading...